AI Article Synopsis
- GrimAge version 2 is an improved DNA methylation-based biomarker that enhances predictions of mortality risk by incorporating new estimators for plasma proteins, specifically log transformed high sensitivity C-reactive protein and hemoglobin A1C.
- It was tested on 13,399 blood samples from various study cohorts and showed better performance than the original GrimAge, particularly for predicting mortality and age-related health issues across different racial and ethnic groups.
- Additionally, GrimAge2 also appears applicable to younger individuals and alternative sample types like saliva, indicating its potential for tracking metabolic syndrome and other health risks, with strong correlations found to type 2 diabetes and morbidity counts.
Article Abstract
We previously described a DNA methylation (DNAm) based biomarker of human mortality risk . Here we describe version 2 of GrimAge (trained on individuals aged between 40 and 92) which leverages two new DNAm based estimators of (log transformed) plasma proteins: high sensitivity C-reactive protein (logCRP) and hemoglobin A1C (logA1C). We evaluate GrimAge2 in 13,399 blood samples across nine study cohorts. After adjustment for age and sex, GrimAge2 outperforms GrimAge in predicting mortality across multiple racial/ethnic groups (meta P=3.6x10 versus P=2.6x10) and in terms of associations with age related conditions such as coronary heart disease, lung function measurement FEV1 (correlation= -0.31, P=1.1x10), computed tomography based measurements of fatty liver disease. We present evidence that GrimAge version 2 also applies to younger individuals and to saliva samples where it tracks markers of metabolic syndrome. DNAm logCRP is positively correlated with morbidity count (P=1.3x10). DNAm logA1C is highly associated with type 2 diabetes (P=5.8x10). DNAm PAI-1 outperforms the other age-adjusted DNAm biomarkers including GrimAge2 in correlating with triglyceride (cor=0.34, P=9.6x10) and visceral fat (cor=0.41, P=4.7x10). Overall, we demonstrate that GrimAge version 2 is an attractive epigenetic biomarker of human mortality and morbidity risk.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9792204 | PMC |
| http://dx.doi.org/10.18632/aging.204434 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Epigenetic age acceleration predicts subject-specific white matter degeneration in the human brain.
Aging Cell
November 2024
Department of Psychology, University of Virginia, Charlottesville, Virginia, USA.
Epigenetic clocks provide powerful tools for estimating health and lifespan but their ability to predict brain degeneration and neuronal damage during the aging process is unknown. In this study, we use GrimAge, an epigenetic clock correlated to several blood plasma proteins, to longitudinally investigate brain cellular microstructure in axonal white matter from a cohort of healthy aging individuals. A specific focus was made on white matter hyperintensities, a visible neurological manifestation of small vessel disease, and the axonal pathways throughout each individual's brain affected by their unique white matter hyperintensity location and volume.
View Article and Find Full Text PDFObjective Assessments of Smoking and Drinking Outperform Clinical Phenotypes in Predicting Variance in Epigenetic Aging.
Genes (Basel)
July 2024
Center for Family Research, University of Georgia, Athens, GA 30602, USA.
The reliability of the associations of the acceleration of epigenetic aging (EA) indices with clinical phenotypes other than for smoking and drinking is poorly understood. Furthermore, the majority of clinical phenotyping studies have been conducted using data from subjects of European ancestry. In order to address these limitations, we conducted clinical, physiologic, and epigenetic assessments of a cohort of 278 middle-aged African American adults and analyzed the associations with the recently described principal-components-trained version of GrimAge (i.
View Article and Find Full Text PDFMap of epigenetic age acceleration: A worldwide analysis.
Ageing Res Rev
September 2024
Artificial Intelligence Research Center, Institute of Information Technologies, Mathematics and Mechanics, Lobachevsky State University, Nizhny Novgorod 603022, Russia; Institute of Biogerontology, Lobachevsky State University, Nizhny Novgorod 603022, Russia. Electronic address:
We present a systematic analysis of epigenetic age acceleration based on by far the largest collection of publicly available DNA methylation data for healthy samples (93 datasets, 23 K samples), focusing on the geographic (25 countries) and ethnic (31 ethnicities) aspects around the world. We employed the most popular epigenetic tools for assessing age acceleration and examined their quality metrics and ability to extrapolate to epigenetic data from different tissue types and age ranges different from the training data of these models. In most cases, the models proved to be inconsistent with each other and showed different signs of age acceleration, with the PhenoAge model tending to systematically underestimate and different versions of the GrimAge model tending to systematically overestimate the age prediction of healthy subjects.
View Article and Find Full Text PDFEpigenetic-based age acceleration in a representative sample of older Americans: Associations with aging-related morbidity and mortality.
Proc Natl Acad Sci U S A
February 2023
Davis School of Gerontology, University of Southern California, Los Angeles, CA 90089.
Biomarkers developed from DNA methylation (DNAm) data are of growing interest as predictors of health outcomes and mortality in older populations. However, it is unknown how epigenetic aging fits within the context of known socioeconomic and behavioral associations with aging-related health outcomes in a large, population-based, and diverse sample. This study uses data from a representative, panel study of US older adults to examine the relationship between DNAm-based age acceleration measures in the prediction of cross-sectional and longitudinal health outcomes and mortality.
View Article and Find Full Text PDFDNA methylation GrimAge version 2.
Aging (Albany NY)
December 2022
Dept. of Human Genetics, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA.
Article Synopsis
- GrimAge version 2 is an improved DNA methylation-based biomarker that enhances predictions of mortality risk by incorporating new estimators for plasma proteins, specifically log transformed high sensitivity C-reactive protein and hemoglobin A1C.
- It was tested on 13,399 blood samples from various study cohorts and showed better performance than the original GrimAge, particularly for predicting mortality and age-related health issues across different racial and ethnic groups.
- Additionally, GrimAge2 also appears applicable to younger individuals and alternative sample types like saliva, indicating its potential for tracking metabolic syndrome and other health risks, with strong correlations found to type 2 diabetes and morbidity counts.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!